標題: Titlebook: Early Phase Cancer Immunotherapy; Sandip Pravin Patel,Razelle Kurzrock Book 2018 Springer International Publishing AG 2018 Immunotherapy.T [打印本頁] 作者: Heel-Spur 時間: 2025-3-21 18:38
書目名稱Early Phase Cancer Immunotherapy影響因子(影響力)
書目名稱Early Phase Cancer Immunotherapy影響因子(影響力)學科排名
書目名稱Early Phase Cancer Immunotherapy網(wǎng)絡公開度
書目名稱Early Phase Cancer Immunotherapy網(wǎng)絡公開度學科排名
書目名稱Early Phase Cancer Immunotherapy被引頻次
書目名稱Early Phase Cancer Immunotherapy被引頻次學科排名
書目名稱Early Phase Cancer Immunotherapy年度引用
書目名稱Early Phase Cancer Immunotherapy年度引用學科排名
書目名稱Early Phase Cancer Immunotherapy讀者反饋
書目名稱Early Phase Cancer Immunotherapy讀者反饋學科排名
作者: 全部逛商店 時間: 2025-3-22 00:08 作者: 講個故事逗他 時間: 2025-3-22 04:17
Book 2018s and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.作者: 地名詞典 時間: 2025-3-22 05:13 作者: canvass 時間: 2025-3-22 10:31
Current Cancer Researchhttp://image.papertrans.cn/e/image/300797.jpg作者: 合群 時間: 2025-3-22 16:37
Early Phase Cancer Immunotherapy978-3-319-63757-0Series ISSN 2199-2584 Series E-ISSN 2199-2592 作者: 合群 時間: 2025-3-22 19:14
https://doi.org/10.1007/978-3-662-48739-6e and infiltrating immune spectra of individual patient tumors offers mechanistic insights for combination therapy selection. Immunotherapeutic approaches through immune checkpoint blockade or stimulation, immune cell therapies, as well as tumor?vaccination are being studied as mono and combination 作者: hypertension 時間: 2025-3-22 21:18 作者: 細胞 時間: 2025-3-23 02:40
https://doi.org/10.1007/978-3-662-05840-4e system to view cancer cells as a foreign presence. The recent success demonstrated by immune checkpoint inhibition in melanoma has launched a boom in immune checkpoint inhibitor trials in several different histologies, but these unfortunately have not shown the same outcome as melanoma. There stil作者: 冥界三河 時間: 2025-3-23 07:07
https://doi.org/10.1007/978-3-662-05841-1n that radiologic responses to immunotherapy can differ from traditional cytotoxic therapy, as do the complications of treatment. Inflammatory response to immunotherapy may mimic actual progression radiologically, an entity known as pseudoprogression. As advances in immunotherapy continue, radiologi作者: endarterectomy 時間: 2025-3-23 13:00
?rztlicher Ratgeber für Auslandsaufenthalteerapy can be “designed” to target almost any specific tumor antigen to mediate an immune response. This strategy has the ability to overcome or complement some limitations of other immunotherapies such as antibody-mediated checkpoint blockade. Unlike endogenous T cells, CAR T cells recognize tumor-s作者: ALIEN 時間: 2025-3-23 15:17
?rztlicher Ratgeber für Auslandsaufenthaltey the adaptive immune response and can work synergistically with checkpoint blockade immunotherapy (CBI) to induce potent endogenous antitumor responses. Preclinical models have demonstrated a potential ability of RT to prime the immune system and augment the efficacy of CBI. Retrospective clinical 作者: 矛盾 時間: 2025-3-23 18:10 作者: Arresting 時間: 2025-3-24 01:19 作者: minaret 時間: 2025-3-24 02:24 作者: 凌辱 時間: 2025-3-24 07:48 作者: Cantankerous 時間: 2025-3-24 10:55
Marion Burckhardt,Andreas Maier-Hasselmanncal progress continues, there is a convergence of these therapeutic approaches as a dynamic interface between the tumor and the supporting environment. Immune therapy drives adaptive changes in tumor oncogenic pathways just as oncogenic pathways shape the tumor microenvironment. This chapter explore作者: mitral-valve 時間: 2025-3-24 18:47 作者: Initial 時間: 2025-3-24 20:09
https://doi.org/10.1007/978-3-662-05840-4otherapy. This is both true in community practice using immunotherapy treatment for their patients and for academic clinicians involved in designing and conducting immunotherapy clinical trials who are essential in developing correlative studies to evaluate potential biomarkers. Here in this chapter作者: 造反,叛亂 時間: 2025-3-25 01:20
?rztlicher Ratgeber für Auslandsaufenthaltells have been used most successfully to treat patients with acute myelogenous leukemia. However, many trials and strategies are being developed to engineer NK cells to better target solid tumors. For cell-based therapies to gain widespread clinical utility, optimization of their manufacturing, admin作者: delegate 時間: 2025-3-25 06:18 作者: 宣稱 時間: 2025-3-25 09:05 作者: Ingenuity 時間: 2025-3-25 12:16
https://doi.org/10.1007/978-3-642-92213-8ting genomically targeted therapies with immune checkpoint inhibitors, such as monoclonal antibodies targeting cytotoxic T-lymphocyte associated antigen 4, programmed cell death protein 1, and PD-1 ligand 1, as well as the clinical status of key combination trials.作者: grotto 時間: 2025-3-25 18:33
Primer on Cancer Immunotherapy and the Targeting of Native Proteins,sient cellular interfaces. Methods for evaluating the presence and function of native proteins for therapeutic targeting necessitates resolving for tumor–immune cellular interactions to understand which cell type is expressing which native protein isoform in the contextual (variably inflamed) tumor 作者: Alopecia-Areata 時間: 2025-3-25 21:08 作者: 熟練 時間: 2025-3-26 00:15
Cellular Therapy,lls have been used most successfully to treat patients with acute myelogenous leukemia. However, many trials and strategies are being developed to engineer NK cells to better target solid tumors. For cell-based therapies to gain widespread clinical utility, optimization of their manufacturing, admin作者: Ingrained 時間: 2025-3-26 06:57
Combinatorial Checkpoint Blockade Immunotherapy and Radiation, details of the abscopal effect and demonstrate the clinical efficacy of combined RT and CBI in treating cancer in both the definitive and metastatic setting. Here we review select preclinical and clinical data on radiation checkpoint blockade combinations.作者: dowagers-hump 時間: 2025-3-26 11:53
Immune Checkpoint Combinations with Inflammatory Pathway Modulators,exert downstream effects on immunosuppressive elements such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) which inhibit the function of effector T cells, NK cells, and dendritic cells, promoting immune tolerance and tumor growth. We herein review three targets for inflam作者: Efflorescent 時間: 2025-3-26 13:22
Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials,ting genomically targeted therapies with immune checkpoint inhibitors, such as monoclonal antibodies targeting cytotoxic T-lymphocyte associated antigen 4, programmed cell death protein 1, and PD-1 ligand 1, as well as the clinical status of key combination trials.作者: Bother 時間: 2025-3-26 20:08 作者: 敵手 時間: 2025-3-26 23:41
2199-2584 torial strategies.Discusses about safety/toxicity determinatThis volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting 作者: 和平主義 時間: 2025-3-27 03:17 作者: maudtin 時間: 2025-3-27 06:01
Die Mutter mit dem kranken S?uglingrials with immunotherapies as single agents or in various combinations with another immunotherapy, targeted therapy, radiation therapy, or chemotherapy. Available data from new studies may provide additional insight for clinical PK and PD for immunotherapies in new patient populations.作者: Aphorism 時間: 2025-3-27 10:47
https://doi.org/10.1007/978-3-662-05841-1 expedited. This chapter will review the standardized methods of radiologically assessing tumor response to traditional cytotoxic chemotherapy as opposed to immunotherapy. It will review the entity and imaging findings of pseudoprogression, and it will also depict the radiologic findings of immune-related pneumonitis and colitis.作者: Palliation 時間: 2025-3-27 16:56
,Die ?rztliche Schweigepflicht,studies with these combinations have been promising; however, some treatment regimens (e.g., durvalumab plus osimertinib, nivolumab plus ipilimumab 3?mg/kg) have had unacceptable safety profiles, and particular attention should be paid to the potential for new toxicities with combination immunotherapies.作者: 圍巾 時間: 2025-3-27 20:09
Pharmacokinetics and Pharmacodynamics of Immunotherapy,rials with immunotherapies as single agents or in various combinations with another immunotherapy, targeted therapy, radiation therapy, or chemotherapy. Available data from new studies may provide additional insight for clinical PK and PD for immunotherapies in new patient populations.作者: 機警 時間: 2025-3-27 22:21 作者: 謊言 時間: 2025-3-28 03:06
Thoracic Immunotherapy,studies with these combinations have been promising; however, some treatment regimens (e.g., durvalumab plus osimertinib, nivolumab plus ipilimumab 3?mg/kg) have had unacceptable safety profiles, and particular attention should be paid to the potential for new toxicities with combination immunotherapies.作者: 使殘廢 時間: 2025-3-28 06:59
Melanoma Immunotherapy,. Immune therapy drives adaptive changes in tumor oncogenic pathways just as oncogenic pathways shape the tumor microenvironment. This chapter explores examples of current and developing therapies at the synapse between intrinsic oncogene signaling and the tumor microenvironment to improve patient outcomes.作者: FISC 時間: 2025-3-28 11:27 作者: paleolithic 時間: 2025-3-28 15:31 作者: osteocytes 時間: 2025-3-28 20:59 作者: 創(chuàng)新 時間: 2025-3-28 22:55 作者: Herd-Immunity 時間: 2025-3-29 04:06
Pharmacokinetics and Pharmacodynamics of Immunotherapy, viruses in eliciting immune responses against tumor cells with promising results in patients. This chapter highlights some of the immunotherapies that are in late-stage development or have received regulatory approval and summarizes their mechanisms of action, pharmacokinetics (PK), and pharmacodyn作者: infarct 時間: 2025-3-29 10:56 作者: 有幫助 時間: 2025-3-29 14:20 作者: 神圣在玷污 時間: 2025-3-29 18:19 作者: anarchist 時間: 2025-3-29 21:18
